At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
GX-I7drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Dose-escalation Study to Evaluate the Safety, Tolerability, and the Lymphocyte Increasing Effects of GX-I7 Intramuscular Administration in Patients With Glioblastoma
In Brief
A Phase 1 clinical trial evaluating GX-I7 for Newly Diagnosed Glioblastoma. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Patients will be enrolled in two stages: * Dose-escalation stage: Approximately 12-24 patients will be enrolled.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNewly Diagnosed Glioblastoma
CountriesSouth Korea
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedAug 2018
Primary CompletionSep 2020
TodayJul 2026
First PostedAug 7, 2018
Enrollment StartJun 20, 2018
Primary CompletionSep 25, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.9 years ago
Interventions
GX-I7drug
During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.